Lv7
5000 积分 2022-10-10 加入
Linker Design for The Antibody Drug Conjugates: A Comprehensive Review
4天前
已完结
Industry Perspective on the Selection of Regulatory Starting Materials for Synthetic Peptides
21天前
已完结
The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress
21天前
已完结
Risk Assessment and Control of N-Nitrosamines in Antibody–Drug Conjugates: Current Industry Practices
21天前
已完结
Strategies for UF/DF-Based Impurity Removal in the Post-conjugation Purification of Antibody–Drug Conjugates
24天前
已完结
Considerations for Starting Material Designation for Drug-Linkers in Antibody–Drug Conjugates
24天前
已完结
The Nonclinical Safety Assessment of a Novel Anti-CEACAM5 Antibody Exatecan Conjugate Predicts a Low Risk for Interstitial Lung Disease (ILD) in Patients—The Putative Mechanism Behind ILD
1个月前
已完结
Therapeutic potential of antibody-drug conjugates possessing bifunctional anti-inflammatory action in the pathogenies of rheumatoid arthritis
2个月前
已完结
Quality Control for Incoming Raw Materials Beyond Identity and Purity: Case Studies from Recent Merck API Manufacturing Processes
2个月前
已完结
Synthetic Approaches to the New Drugs Approved during 2023
3个月前
已完结
皖公网安备34019202002308
